Meta‐analysis: ertapenem for complicated intra‐abdominal infections

Falagas, Matthew E.; Peppas, George; Makris, Gregory C.; Karageorgopoulos, Drosos E.; Matthaiou, Dimitrios K.

doi:10.1111/j.1365-2036.2008.03642.x

Cited by 28 publications

(18 citation statements)

References 34 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The five meta-analyses studying different antibiotic regimens for the treatment of intra-abdominal infections compared ertapenem with other antibiotic regimens, 50 clindamycin/aminoglycoside with b-lactam monotherapy, 55 ciprofloxacin/metronidazole with b-lactam based regimens, 65 aminoglycosides with other antibiotic regimens, 73 and meropenem with other antimicrobials. 79 Ertapenem was found to be as effective as other antimicrobials for the treatment of complicated intra-abdominal infections.…”

Section: Meta-analyses Focusing On Topics Other Than Antibiotic Prophmentioning

confidence: 99%

Meta-analysis on Surgical Infections

Matthaiou¹,

Peppas²,

Falagas³

2009

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Section: Meta-analyses Focusing On Topics Other Than Antibiotic Prophmentioning

confidence: 99%

Meta-analysis on Surgical Infections

Matthaiou¹,

Peppas²,

Falagas³

2009

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

“…A non-inferiority design was selected for this randomised clinical trial because the study drugs have shown similar efficacy to standard ␤-lactam-based antimicrobial regimens [8][9][10]12,13,16]. …”

mentioning

confidence: 99%

Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study

Waele

Tellado

Alder

et al. 2013

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Antibiotic therapy for complicated intra-abdominal infections (cIAIs) should provide broad-spectrum coverage both Gram-positive and Gram-negative microorganisms. The PROMISE study compared the clinical and bacteriological efficacy and safety of moxifloxacin versus ertapenem for the treatment of cIAIs. This randomised, prospective, double-dummy, double-blind, multicentre trial was designed as a non-inferiority study. The safety and efficacy of 5-14 days of daily intravenous moxifloxacin (400mg) or ertapenem (1g) were compared in patients with cIAIs requiring surgery and parenteral antibiotic therapy. The primary and secondary endpoints included clinical and bacteriological responses at 21-28 days after the end of treatment (TOC), respectively. Of 830 enrolled patients, 699 were efficacy valid. Moxifloxacin was non-inferior to ertapenem regarding clinical success [89.5% (315/352) versus 93.4% (324/347); 95% confidence interval (CI) -7.9%, 0.4%]. There were no significant differences between groups for any of the primary causes or types of cIAI regarding clinical response. Bacteriological success was achieved in 86.5% (257/297) of moxifloxacin-treated patients and 90.2% (249/276) of ertapenem-treated patients (95% CI -9.0%, 1.5%). There were no major differences between groups regarding the frequency or types of organisms eradicated. The incidence of adverse events (AEs) was higher with moxifloxacin than ertapenem (P=0.039), however a similar number of drug-related AEs was seen in each group (P=1.000). Wound infections, nausea and increased lipase were the most commonly reported AEs with both agents. The results show that moxifloxacin is a valuable treatment option for a range of community-acquired cIAIs with mild-to-moderate severity.

show abstract

“…The results of in vitro and clinical studies showed that the use of ertapenem did not decrease susceptibility of P. aeruginosa, Enterobacteriaceae or other gram-negative pathogens to carbapenems [7,12].…”

Section: Discussionmentioning

confidence: 98%

The Use of Ertapenem in Postoperative Polymicrobial Peritonitis - case report

Gavril

Grosu²,

Amancei³

et al. 2014

Arch Clin Cases

View full text Add to dashboard Cite

A 59 year-old male patient diagnosed with cecal cancer, surgically treated -right hemicolectomy with ileotransverse anastomosis suddenly presented in the 5th postoperative day fever, hypotension, abdominal pain, and vomiting faeces. The intraoperatory diagnosis was postoperative peritonitis due to anastomotic leak; exploratory laparotomy, segmental colectomy, transverse ileostomy, lavage and drainage were performed. Before surgical reintervention, blood cultures were performed and empirical antiinfective therapy was started using ertapenem, vancomycin and fluconazole. A postoperative ICU admission was decided due to septic shock and MODS: acute respiratory failure, acute cardio-circulatory failure, coagulopathy and metabolic acidosis, which required complex treatment: ventilatory support, haemodynamic optimization, antibiotics, analgesia, deep venous thromboembolism prophylaxis, nutrition. In the 3 rd day after reintervention, microbiological examination of the intraoperatory collected peritoneal fluid identified a triple germ association: Escherichia coli, Enterococcus faecalis and Proteus mirabilis, which were sensitive to the chosen antibiotics; the blood cultures were sterile. After 3 days of severe evolution, the multiple organ dysfunction gradually improved and the patient was discharged from ICU 10 days later.

show abstract

Meta‐analysis: ertapenem for complicated intra‐abdominal infections

Abstract: SUMMARY Background

Cited by 28 publications

References 34 publications

Meta-analysis on Surgical Infections

Meta-analysis on Surgical Infections

Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study

The Use of Ertapenem in Postoperative Polymicrobial Peritonitis - case report

Contact Info

Product

Resources

About